Mechanism of Stem Cell Therapy Bemdaneprocel for Parkinson Disease: Amit Rakhit, MD
October 9th 2024The chief medical officer and chief development officer at BlueRock Therapeutics discussed the promise behind bemdaneprocel and its unique mechanism of action relative to other Parkinson disease treatments. [WATCH TIME: 3 minutes]
Key Updates in SMA Diagnosis: What Clinicians Should Know
October 9th 2024In this episode, our panel of experts delves into the latest updates on spinal muscular atrophy diagnosis, focusing on the critical role of newborn screening, early intervention, and evolving classification methods for improved patient outcomes.
Distinct Alzheimer Disease Subtypes Using Proteomic Fingerprints: Fiona Elwood, PhD
October 8th 2024The disease area stronghold leader in neurodegeneration at Johnson & Johnson discussed data presented at AAIC 2024 highlighting different subtypes of Alzheimer disease that may lead to more personalized treatments. [WATCH TIME: 4 minutes]
Current Treatment Options for Dravet Syndrome
October 7th 2024The panelist discusses how the goal of Dravet syndrome treatment is to reduce seizure frequency and severity, typically starting with initial treatments like valproate and clobazam and potentially escalating to combination therapies including options such as cannabidiol, with the overall aim of improving patients’ quality of life and developmental outcomes
Dravet Syndrome: Comorbidities and Patient Quality of Life
October 7th 2024Scott Perry, MD, discusses how pediatric patients with Dravet syndrome often experience various comorbidities alongside seizures, including developmental delays, behavioral issues, and sleep disturbances, which significantly impact quality of life, especially when diagnosis is delayed, necessitating comprehensive management strategies.
Advancing Multiple Sclerosis Diagnosis With the 2024 Criteria Revision: Xavier Montalban, MD, PhD
October 7th 2024The chair of neurology at Hospital Universitari Vall d’Hebron talked about the revision of the MS diagnostic criteria that will integrate new evidence, biological markers, and advanced MRI findings to enable earlier and more precise diagnoses. [WATCH TIME: 4 minutes]
Patient-Centric Care and Shared Decision-Making in Parkinson’s Disease
October 4th 2024Dr. Isaacson discusses how patient-centric, personalized care in Parkinson's Ddisease (PD) focuses on tailoring treatment to individual patient needs and preferences, contrasting with pharmacological-centered care by emphasizing shared decision-making and the holistic integration of wellness strategies.
Potential Promise Behind ATH434 for Multiple System Atrophy: Daniel Claassen, MD, MS
October 2nd 2024The director of the Huntington’s Disease Clinic at Vanderbilt University Medical Center gave commentary on the unique development of ATH434, its ability to target iron accumulation, and how it may slow disease progression in multiple system atrophy. [WATCH TIME: 3 minutes]
Positive 24-Month Data of Cell Therapy Bemdaneprocel in Parkinson Disease: Amit Rakhit, MD
October 1st 2024The chief medical officer and chief development officer at BlueRock Therapeutics provided perspective on newly presented data investigating a cell therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]
Mechanism Behind Ulixacaltamide to Treat Essential Tremor: Marcio Souza
October 1st 2024The president and chief executive officer at Praxis Precision Medicine provided clinical insight on the promising build of ulixacaltamide, an investigational, selective agent in development for essential tremor. [WATCH TIME: 3 minutes]
Expert Dravet Syndrome Overview
September 30th 2024Scott Perry, MD, discusses how Dravet syndrome is a rare genetic epilepsy characterized by frequent, prolonged seizures beginning in infancy, often accompanied by developmental delays and other health issues that persist and evolve as patients age.
Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD
September 30th 2024Jacqueline Nicholas, MD MPH discusses the importance of targeting NMOSD through different mechanisms of action and highlight key points for communicating with neurologists about the role of the complement system in the disease.
Potential of Device-Assisted Therapy for Advanced-Stage Parkinson Disease: David Devos, MD, PhD
September 29th 2024The neuropharmacologist at the University of Lille, in France, provided commentary on promising results from the phase 1/2 DIVE-I trial assessing the safety and efficacy of a device-assisted therapy in Parkinson disease. [WATCH TIME: 6 minutes]
A Melting Pot of Strategies and Collaboration at the 2025 MDA Conference: Sharon Hesterlee, PhD
September 26th 2024The chief research officer of the Muscular Dystrophy Association talked about what is to be expected at the 2025 MDA Conference, held March 16-19, in Dallas, Texas. [WATCH TIME: 5 minutes]
Using the DAAE Score to Advance Personalized Medicine for Multiple Sclerosis: Tom Fuchs, MD, PhD
September 25th 2024The postdoctoral researcher at Amsterdam University Medical Center talked about the DAAE score 2.0 which offers an improved, validated clinical tool to predict the risk of transitioning to secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]
Optimizing Care for SCN8A Epilepsy and Related Disorders: Gabi Conecker; JayEtta Hecker
September 24th 2024Representatives from the SCN8A Alliance discussed ways to improve the quality of life for children with SCN8A-related epilepsy, highlighting the critical role of early genetic diagnosis and targeted interventions. [WATCH TIME: 4 minutes]
Treatment Options to Manage and Prevent Relapses in NMOSD
September 23rd 2024Jacqueline Nicholas, MD, MPH, discusses available treatment options for NMOSD, including management of acute phases, relapses, and symptom control, as well as how both traditional and newer therapies address different aspects of NMOSD pathophysiology.
Key Challenges and Future Directions of Targeting mTOR for Epileptic Disorders: Ghayda Mirzaa, MD
September 23rd 2024The principal investigator at Seattle Children’s Research Institute described some of the ongoing questions that remain with developing therapeutics that target mTOR signaling pathway in pediatric epilepsy conditions. [WATCH TIME: 3 minutes]
A Clinical Approach to Recognizing and Diagnosing Restless Leg Syndrome: Shalini Paruthi, MD, FAASM
September 23rd 2024In honor of Restless Legs Syndrome Awareness Day, held September 23, 2024, the American Academy of Sleep Medicine spokesperson talked about the condition and its impact on the United States population as well as the criteria to diagnose it. [WATCH TIME: 3 minutes]